Barcelona, 13th May 2024. D-Sight, a pioneering spin-off company of Vall d’Hebron Research Institute (VHIR) dedicated to the discovery and development of new innovative therapeutic approaches for the treatment of neurodegenerative diseases of the retina; is thrilled to announce its strategic partnership with Famar Group, a European contract manufacturing and development organization serving the pharmaceutical industry.
This collaboration marks a significant milestone for both entities, as they join forces to accelerate the development and production of clinical batches for D-Sight’s eye drops solution intended for the treatment of early stages of diabetic retinopathy. Leveraging Famar Group’s state-of-the-art facilities and expertise in CMC and GMP manufacturing, D-Sight aims to streamline the production process and ensure the highest quality standards for its innovative therapeutic solutions.
FAMAR has a 75-year track record of delivering quality and value to customers across all finished dosage forms including sterile liquids, solids, and semi-solids. The company has a workforce of 1,850 employees across a network of six manufacturing sites and two R&D centers in Spain, Italy, and Greece. FAMAR currently supplies 1.700 different products to more than 80 international markets.
Shaping the future of neurodegenerative diseases of the retina
“We are excited to embark on this collaborative journey with Famar Group” said Carla Maté Goldar, CEO and co-founder of D-Sight. “Their reputation for excellence in manufacturing and their experience in pharmaceutical development in the ophthalmic sector aligns perfectly with our commitment to delivering safe and effective therapies to patients in need. This partnership represents a significant step forward in advancing our mission to improve the quality of life of diabetic patients with visual impairment”.
As part of the collaboration, Famar Group will provide comprehensive manufacturing services, including process optimization, scale-up, and production of clinical batches for regulatory submission. By outsourcing manufacturing activities to Famar Group, D-Sight can focus its resources on advancing research and development initiatives and accelerating the path to market for its promising therapeutic candidate.
“We are delighted to collaborate with D-Sight on this innovative project,” said Konstantinos Rengis, Famar Groups’s CEO. “Our team is dedicated to supporting D-Sight’s vision by delivering high-quality manufacturing solutions tailored to their unique needs. Together, we are poised to make a significant impact on the future of the treatment of neurodegenerative diseases of the retina”.
The partnership between D-Sight and Famar Group underscores the importance of collaboration in driving innovation within the life sciences industry. By combining their respective strengths and resources, both companies are well-positioned to accelerate the development and commercialization of novel therapies that have the potential to transform patient care.